Send the following on WhatsApp
Continue to Chat天演藥業宣佈將在2022年ESMO上公佈抗CTLA-4安全抗體ADG126單一療法中期數據,其針對晚期實體瘤患者展示出抗CTLA-4前所未有的安全性,抗腫瘤活性與藥代動力學特徵 https://geneonline.news/%e5%a4%a9%e6%bc%94%e8%97%a5%e6%a5%ad%e5%ae%a3%e4%bd%88%e5%b0%87%e5%9c%a82022%e5%b9%b4esmo%e4%b8%8a%e5%85%ac%e4%bd%88%e6%8a%97ctla-4%e5%ae%89%e5%85%a8%e6%8a%97%e9%ab%94adg126%e5%96%ae%e4%b8%80%e7%99%82/